Edmund Dunn's departure as Controller of Monte Rosa Therapeutics, Inc. was reported, effective April 3, 2026; the filing names no successor. As of November 14, 2026, Monte Rosa Therapeutics, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on February 10, 2026, naming 1 departure (Form 8-K, February 10, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Monte Rosa Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Monte Rosa Therapeutics, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-02-10. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Monte Rosa Therapeutics, Inc. files it.
Also on the record for Monte Rosa Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2026 | Stake report, Schedule 13G, by Vestal Point Capital, LP | 5.4% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Montanova Capital, LLC | 4.2% of the class | 5%+ stakes | Source |
| July 8, 2026 | Stake report, Schedule 13G/A, by T. Rowe Price Associates, Inc. | 10.5% of the class | 5%+ stakes | Source |
| July 6, 2026 | Stake report, Schedule 13D/A, by New Enterprise Associates 17, L.P. | 7.9% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Baker Bros. Advisors LP | 9.99% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by BVF PARTNERS L P/IL | 6.3% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Chen Yu | 5.5% of the class | 5%+ stakes | Source |
| April 22, 2026 | Stake report, Schedule 13G/A, by Adam Goulburn | 8.1% of the class | 5%+ stakes | Source |
| March 19, 2026 | Stake report, Schedule 13D/A, by New Enterprise Associates 17, L.P. | 9.7% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Baker Bros. Advisors LP | 6.7% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by BVF PARTNERS L P/IL | 5.9% of the class | 5%+ stakes | Source |
| January 21, 2026 | Stake report, Schedule 13G/A, by Adam Goulburn | 8.7% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Monte Rosa Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Monte Rosa Therapeutics, Inc. and the records around it.
Monte Rosa Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Who owns it
Companies that share a holder
- Versant Venture Capital VI, L.P. also filed stake reports on 3 other companies: Tempest Therapeutics, Inc. (Apr 2026), LENZ Therapeutics, Inc. (Nov 2025), LAVA Therapeutics N.V. (Sep 2025)
- New Enterprise Associates 17, L.P. also filed stake reports on 4 other companies: Inventiva S.A. (Apr 2026), Korro Bio, Inc. (Mar 2026), SpyGlass Pharma, Inc. (Feb 2026)
- Avoro Capital Advisors LLC also filed stake reports on 18 other companies: Arrowhead Pharmaceuticals, Inc. (Aug 2026), Avalo Therapeutics, Inc. (Aug 2026), Hemab Therapeutics Holdings, Inc. (Aug 2026)
Watch Monte Rosa Therapeutics, Inc.
Get an email when Monte Rosa Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Monte Rosa Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Monte Rosa Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Monte Rosa Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 20 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-02-10 | Out | Controller | 2026-04-03 | 8-K, 2026-02-10 |
Why did they leave? What the filings say
For each named departure below, the sentence from the company's own filing that gives a reason, word for word. Where a filing gives none, it says so here; nothing is inferred.
- Edmund Dunn, Controller (filed 2026-02-10):
Mr. Dunn's retirement and departure from the Company was not because of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
Who leads Monte Rosa Therapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Controller: Edmund Dunn, departure reported, effective 2026-04-03 (filed 2026-02-10). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Monte Rosa Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Controller at Monte Rosa Therapeutics, Inc., with the record behind each one.
Find candidates like Controller at Monte Rosa Therapeutics, Inc.Every change, in the filing's words
Departing: Edmund Dunn, Controller, effective 2026-04-03
On January 9, 2026, Edmund Dunn informed us of his intent to retire from the role of SVP, Corporate Controller and Principal Accounting Officer of Monte Rosa Therapeutics, Inc. (the " Company "), effective as of April 3, 2026.
- Mr. Dunn will not receive any severance payments or benefits in connection with his departure.
- Effective April 3, 2026, Matthew Bowen, currently an employee of the Company, will succeed Mr. Dunn as Corporate Controller and Principal Accounting Officer of the Company.
- Mr. Bowen, age 37, joined the Company's finance department following the Company's initial public offering in June 2021 to support the enhanced financial reporting and compliance requirements associated with operating as a public company.
- Since joining the Company, Mr. Bowen has served in roles of increasing responsibility over the past nearly five years, most recently as Director, Finance.
- Prior to joining the Company, Mr. Bowen spent seven years in the audit and assurance practice at Ernst & Young LLP, where he primarily worked on audits of large public companies.
- Mr. Bowen holds a Bachelor of Science and a Master's in Accounting from Bryant University and is a licensed Certified Public Accountant in the Commonwealth of Massachusetts.
Tools for this story
Each opens in a new tab, filled in for Monte Rosa Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
